Congress extended the rare pediatric priority review voucher (PPRV/PRV) program through 2029 as part of a broader spending package that also included pharmacy benefit manager (PBM) transparency measures. The Biotechnology Innovation Organization (BIO) publicly welcomed the reauthorization, calling it a bipartisan victory that preserves an important incentive for pediatric rare‑disease drug development. The package reduces short‑term regulatory uncertainty for companies dependent on transferrable vouchers as commercialization financing.